Reply To: Traders Market Weekly: Liberty Dichotomy; Paris Burns Ahead of Independance Day

#61074
Truman
Participant

FibroGen (FGEN 3.70, -12.35, -77.0%): announces topline results from Phase 3 ZEPHYRUS-1 study of pamrevlumab for the treatment of idiopathic pulmonary fibrosis; Study did not meet the primary endpoint